These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1414906)

  • 1. Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects.
    Hoon TJ; McCollam PL; Beckman KJ; Hariman RJ; Bauman JL
    Am J Cardiol; 1992 Oct; 70(11):1072-6. PubMed ID: 1414906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.
    Ahmed JH; Godden J; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1993 Aug; 36(2):93-8. PubMed ID: 8398588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of food on the bioequivalence of different verapamil sustained-release formulations.
    Waldman SA; Morganroth J
    J Clin Pharmacol; 1995 Feb; 35(2):163-9. PubMed ID: 7751427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil.
    Berk SI; Beckman K; Hoon TJ; Hariman RJ; Hu D; Siegel FP; Bauman JL
    Pharmacotherapy; 1992; 12(1):33-9. PubMed ID: 1549537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.
    Karim A; Piergies A
    Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.
    Schoen MD; Parker RB; Hoon TJ; Hariman RJ; Bauman JL; Beckman KJ
    Am J Cardiol; 1991 Feb; 67(4):300-4. PubMed ID: 1990794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
    Moreland TA; McMurdo ME; McEwen J
    Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Yih BM; Atkinson L; Longstreth J
    J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
    Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of two formulations of verapamil.
    Hla KK; Henry JA; Latham AN
    Br J Clin Pharmacol; 1987 Nov; 24(5):661-4. PubMed ID: 3435694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronopharmacology of intravenous and oral modified release verapamil.
    Dilger K; Eckhardt K; Hofmann U; Kucher K; Mikus G; Eichelbaum M
    Br J Clin Pharmacol; 1999 Apr; 47(4):413-9. PubMed ID: 10233206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates.
    Barbarash RA; Bauman JL; Fischer JH; Kondos GT; Batenhorst RL
    Chest; 1988 Nov; 94(5):954-9. PubMed ID: 3180898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
    McAllister RG; Kirsten EB
    Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.